BENGALURU, Oct 12 (Reuters) - India's Everest Organics Ltd (EVER.BO) said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's (MRK.N) experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.
Money has never been an issue for Everest Medicines. With an essentially open tab from their founders at C-Bridge Capital, the biotech has gone two and a half years racking up drug after drug, bringing in top exec after top exec, and issuing clinical update after update.